Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy switch in virologically suppressed HIV-1 adults
NCT03502005Phase 4Completed
- Sponsor
- Midland Research Group
- Start
- Mar 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Midland Research Group. Started Mar 2018; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03502005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502005.